Spironolactone Against Anthracycline-induced Cardiomyopathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-30

Study Completion Date

2012-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study sought to investigate the whether spironolactone protects the heart against anthracycline-induced cardiotoxicity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity (SPIROTOX)

NCT06005259

Cardiotoxicity Neoplasms Chemotherapy Effect +1 more

NOT_YET_RECRUITING PHASE4

Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy

NCT00125437

Heart Failure, Congestive

TERMINATED NA

Spironolactone in the Treatment of Heart Failure

NCT04727073

Heart Failure with Mid-range Ejection Fraction Heart Failure with Preserved Ejection Fraction

TERMINATED PHASE3

Short Term Spironolactone for Prevention of Acute Kidney Injury After Cardiac Surgery

NCT02417896

Acute Kidney Injuries Kidney Injuries, Acute Kidney Injury, Acute +2 more

UNKNOWN NA

Efficacy of Spironolactone Combined With Antihypertensive Drugs in Patients With Primary Aldosteronism

NCT07137364

Primary Aldosteronism Hypertension

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Anthracyclines are the cornerstone in the treatment of numerous hematological and solid cancers. The most common side effect of anthracycline is cardiotoxicity and this may limits its use and increases the rate of mortality and morbidity. Cardiotoxicity is cumulative, dose dependent, and irreversible. Improvements in protective mechanisms against the cardiotoxicity of anthracycline are important to prevent the discontinuance of these chemotherapeutics.

Spironolactone is an aldosterone antagonist which blocks the last step of the rennin angiotensin aldosterone system (RAAS). The RAAS is one of the most effective systems in remodeling of the myocardium in post-myocardial damage. According to the RALES study, in patients with severe heart failure, 25 mg spironolactone per day in addition to the standard therapy has positive effects, particularly on cardiac fibrosis and on remodeling, and substantially reduces the risk of both morbidity and death. In the EPHESUS study, it has been shown that, after the myocardial damage due to infarction, the administration of aldosterone antagonists had positive effects on the remodeling process, left ventricular ejection fraction and primer end-points. In the present study, we tested the hypothesis that RAAS blockage with spironolactone may reduce the cardiotoxicity of anthracycline group chemotherapeutics.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anthracycline Induced Cardiotoxicity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Spironolactone

patients who randomized to spironolactone administered arm

Group Type ACTIVE_COMPARATOR

Spironolactone

Intervention Type DRUG

Spironolactone

Placebo

Patients who randomized to placebo administered arm

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Spironolactone

Intervention Type DRUG

Placebo

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

25 mg spironolactone orally

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* LVEF \>50%
* first diagnosed breast cancer
* female sex

Exclusion Criteria

* Prior breast cancer and/or prior anthracycline exposure history
* LVEF \<50%
* Use of angiotensin converting enzyme inhibitors, angiotensin receptor blockers and beta blockers
* Creatinin value \>2 mg/dl
* Presence of chronic kidney failure
* Potassium value \>5.3 mg/dl
* Presence of adrenal gland diseases,
* Presence of severe liver failure
* Co-morbidities such as coronary heart disease, hypertension, atrial fibrillation, and valvular heart disease.
* Male patients were excluded for the homogenization of the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No